ECHELON-1 trial data from ASH 2017: controversies and clinical translation
Description: An update on the results of the Phase III ECHELON-1 study (NCT01712490), comparing ABVD vs. AVD plus brentuximab vedotin in the first-line setting for advanced classical Hodgkin Lymphoma, was highly anticipated at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Graham Collins, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses his take on the results presented. Dr Collins highlights the debate around the use of modified progression-free survival (mPFS) as an endpoint, the potential for bias, the use of bleomycin within the ABVD course and the cost-effectiveness of this treatment.
Shared By : VJHemOnc
Posted on : 01/03/18
Added : 6 months ago